The potential biomarkers for thromboembolism detected by SELDI-TOF-MS
The potential biomarkers for thromboembolism detected by SELDI-TOF-MS
复制标题
SELDI-TOF-MS 检测血栓栓塞的潜在生物标志物
DOI：
10.1016/j.thromres.2008.05.019
复制
发表时间：
2009-01-01
影响因子：
7.5
通讯作者：
Song, Shanjun
中科院分区：
文献类型：
--
作者：
Hong, Mei;Zhang, Xiaoping;Song, Shanjun
简介：很少有研究关注通过表面增强激光解吸/电离飞行时间质谱 (SELDI-TOF-MS) 寻找血栓栓塞（动脉和静脉）疾病的特异性生物标志物。材料和方法：我们在 69 个血浆样本中筛选了潜在的生物标志物，其中包括来自 20 名特发性深静脉血栓 (DVT) 患者和 20 名急性心肌梗塞患者的样本(AMI) 和 29 名无血栓栓塞病史的健康对照者。预处理的血浆样品在蛋白质生物系统 IIc 和 SELDI-TOF-MS（Ciphergen Biosystems，弗里蒙特，CA）上进行分析。通过将血浆应用到用铜激活的固定金属亲和捕获 (IMAC-3) ProteinChip 阵列上，生成质荷比 (m/z) 的蛋白质组谱。 结果：根据对 AMI 患者和健康对照之间最佳分离的共同贡献，选择了总准确度为 100% 的三种生物标志物（m/z：分别为 2 667、5 914 和 6 890 Da）的模式。另一种仅由一种生物标志物（m/z：5 914 Da）组成的图案可以完全区分 DVT 患者和对照受试者。为了对 AMI 患者和 DVT 患者进行进一步分析，选择了四种生物标志物（m/z：3 418、5 271、33 378 和 68 125 Da 分别）的模式，总准确度为 82.5%。结论：使用 SELDI-TOF-MS 和 ProteinChip 技术进行血浆蛋白质组分析，在区分血栓形成和血栓形成患者方面具有高灵敏度和特异性。健康的受试者。发现的生物标志物可能在血栓栓塞性疾病的早期诊断方面显示出巨大的潜力。 (C) 2008 Elsevier Ltd. 保留所有权利。
Introduction: Few studies were concerned about searching for specific biomarkers for thromboembolic (arterial and venous) diseases by the use of Surface-Enhanced Laser Desorption/Ionization Time-of-Flight Mass Spectrometry (SELDI-TOF-MS).Materials and Methods: We screened for potential biomarkers in 69 plasma samples, including samples from 20 patients with idiopathetic deep vein thrombosis (DVT), 20 patients with acute myocardial infarction (AMI), and 29 healthy controls without a history of thromboembolism. Pretreated plasma samples were analyzed on the Protein Biology System IIc plus SELDI-TOF-MS (Ciphergen Biosystems, Fremont, CA). Proteomic spectra of mass to charge ratio (m/z) were generated by the application of plasma to immobilized metal affinity capture (IMAC-3) ProteinChip arrays activated with copper.Results: A pattern of three biomarkers (m/z: 2 667, 5 914, and 6 890 Da, respectively) with a total accuracy of 100% was selected based on their collective contribution to the optimal separation between patients With AMI and healthy controls. Another spattern consisting of only one biomarker (m/z: 5 914 Da) could totally discriminate patients with DVT and control subjects. For further analysis between patients with AMI and those with DVT, a pattern of four biomarkers (m/z: 3 418, 5 271, 33 378, and 68 125 Da, respectively) was selected with a total accuracy of 82.5%.Conclusions: Plasma proteomic profiling with SELDI-TOF-MS and ProteinChip technologies provides high sensitivity and specificity in discriminating patients with thrombosis and healthy subjects. The discovered biomarkers might show great potential for early diagnosis of thromboembolic diseases. (C) 2008 Elsevier Ltd. All rights reserved.